Codexis, Inc. (CDXS)
After hours:
| Previous close | 2.7600 |
| Open | 2.7900 |
| Bid | 2.7900 x 200 |
| Ask | 2.8300 x 100 |
| Day's range | 2.7100 - 2.8950 |
| 52-week range | 1.4500 - 4.9100 |
| Volume | |
| Avg. volume | 590,520 |
| Market cap | 196.85M |
| Beta (5Y monthly) | 2.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1200 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.57 |
GlobeNewswireCodexis to Report First Quarter 2024 Financial Results on May 2
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday, May 2, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relation
- GlobeNewswire
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platformREDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agricu
Simply Wall St.Favourable Signals For Codexis: Numerous Insiders Acquired Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
